ReviewInflammatory bowel diseases2026
Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology.
Review in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expanding therapeutic landscape of inflammatory bowel disease has highlighted the need for clear and standardized drug nomenclature to support safe prescribing, pharmacovigilance, international communication, and patient understanding. The World Health Organization's international nonproprietary name system, established in 1953, assigns unique and informative names to medicines. However, the increasing number and diversity of monoclonal antibodies used in inflammatory bowel disease and other diseases have outgrown the capacity of the traditional -mab suffix to convey meaningful structural or functional distinctions. In 2021, the international nonproprietary name system was updated to introduce new suffixes, such as -tug, -bart, -ment, and -mig, that provide more precise information, although these remain unfamiliar to many clinicians. This narrative review explores how international drug naming conventions have evolved and have been applied within the context of inflammatory bowel disease, from early compounds to contemporary engineered therapies, and examines the rationale and clinical relevance of the updated naming framework. Drawing on historical and current literature, as well as policy documents from the World Health Organization's international nonproprietary name expert group, this review charts the development and successive reforms of the naming scheme. As inflammatory bowel disease therapies continue to diversify, understanding this evolving nomenclature is increasingly important for safe prescribing and effective communication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.